Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues		$ 13,117.2	$ 12,172.9	$ 16,071.7
Roche Collaboration Agreement | Ronapreve | Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues		224.3	627.3	361.8
Roche Collaboration Agreement | Ronapreve | Cost of goods sold
Disaggregation of Revenue [Line Items]
Revenues		0.0	0.0	259.6
Roche Collaboration Agreement | Reimbursement of R&D expenses | (R&D expense)/Reduction of R&D expense
Disaggregation of Revenue [Line Items]
Revenues		(1.5)	6.8	128.1
Roche Collaboration Agreement | Other | Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues		$ (13.3)	$ 0.0	$ 0.0